Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03636412 · ClinicalTrials.gov registry record · NA

Improving Frailty With a Rigorous Ambulation Intervention in Lung Transplant Patients

A NA study of Sarcopenia and Mobility Limitation, sponsored by The Cleveland Clinic.

Completed
Registry status
NA
Development phase
200
Enrollment target
1
Study location

NCT03636412 is a NA study of Sarcopenia and Mobility Limitation that has completed, run by The Cleveland Clinic. The registered enrollment target is 200 participants, above the 76-participant average among 41 other Sarcopenia trials with a reported enrollment target (163% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03636412, a NA study of Sarcopenia and Mobility Limitation, has completed, sponsored by The Cleveland Clinic.

COMPLETED
Registry status
NA
Development phase
200 participants
Enrollment target
1
Study location

Study Summary

The objective of this study is to assess the feasibility and effectiveness of dedicated ambulator-assisted physical activity in lung transplant inpatients. The primary hypothesis is that an ambulator-assisted intervention for lung transplant patients will prove feasible and may result in improved frailty, hospital outcomes, including less need for inpatient rehabilitation and shorter length of stay in the hospital.

Interventions

  • OTHER Ambulation

Study Locations (1)

Ohio

  • Cleveland Clinic - Cleveland

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2018-08-15
Est. Completion 2024-12-31
Phase NA

Sponsor

The Cleveland Clinic

688 total trials

What the Registry Record Tells You About NCT03636412

The ClinicalTrials.gov registry entry for NCT03636412 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 76-participant average among 41 other Sarcopenia trials with a reported enrollment target (163% higher). The listed sponsor is The Cleveland Clinic, which has 688 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Sarcopenia appearing as the primary indexed condition, and to 1 intervention - of which Ambulation is the first listed.

NCT03636412 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.

Frequently Asked Questions

What is clinical trial NCT03636412 about?

NCT03636412 is a clinical study titled "Improving Frailty With a Rigorous Ambulation Intervention in Lung Transplant Patients". The objective of this study is to assess the feasibility and effectiveness of dedicated ambulator-assisted physical activity in lung transplant inpatients. The primary hypothesis is that an ambulator-assisted intervention for lung transplant patients will prove feasible and may result in improved fr...

What is the current status of trial NCT03636412?

This trial is currently completed. It is a NA study. The enrollment target is 200 participants. The study started on 2018-08-15. Estimated completion is 2024-12-31.

What conditions does trial NCT03636412 study?

This clinical trial studies the following conditions: Sarcopenia, Mobility Limitation, Transplant-Related Disorder, Frail Elderly Syndrome, Lung Graft Dysfunction.

What interventions are being tested in trial NCT03636412?

The interventions under investigation include: Ambulation (OTHER).

Who is sponsoring clinical trial NCT03636412?

This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03636412 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Sarcopenia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.